Danish pharmaceutical giant Novo Nordisk has announced a new 800-million-yuan (approximately USD 111.9 million) investment to expand its quality-control laboratory in Tianjin, China.
The memorandum of cooperation was signed on Tuesday 8 July with the municipal authorities of Tianjin, further strengthening Novo Nordisk’s position in the region. The new expansion will bring the company’s cumulative investment in the city to over 10 billion yuan.
Located in the Tianjin Economic-Technological Development Area, the site is one of Novo Nordisk’s strategic global manufacturing hubs. The facility employs about 1,800 people and plays a key role in the company’s global supply chain.
Construction on a separate 4-billion-yuan sterile production expansion began in March 2024. The newly announced laboratory expansion will span 18,000 square meters and include advanced chemical, microbiological, and biological testing facilities. It is expected to be completed by the end of 2026.
Founded in 1923 and headquartered in Denmark, Novo Nordisk operates in 80 countries with a global workforce of approximately 77,400. The company specializes in treatments for diabetes, obesity, rare blood and endocrine disorders.
Source: english.news.cn
